Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
5-2020

Evaluating the Association Between Vasopressin Use and InHospital Mortality in Patients with Septic Shock
Michael Pasqualicchio
Baptist Hospital of Miami, michaelpa@baptisthealth.net

Heidi Clarke
Baptist Hospital of Miami, heidic@baptisthealth.net

Jonathan Kline
Baptist Hospital of Miami, JonathanDK@baptisthealth.net

Payal Patel
Baptist Hospital of Miami, PayalDP@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications
Part of the Chemicals and Drugs Commons, Critical Care Commons, and the Pharmacy and
Pharmaceutical Sciences Commons

Citation
Pasqualicchio, Michael; Clarke, Heidi; Kline, Jonathan; and Patel, Payal, "Evaluating the Association
Between Vasopressin Use and In-Hospital Mortality in Patients with Septic Shock" (2020). All
Publications. 3535.
https://scholarlycommons.baptisthealth.net/se-all-publications/3535

This Conference Lecture -- Open Access is brought to you for free and open access by Scholarly Commons @
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact
Carrief@baptisthealth.net.

Evaluating the association between
vasopressin use and in-hospital
mortality in patients with septic shock
Michael Pasqualicchio, PharmD, BCPS
PGY-2 Critical Care Pharmacy Resident
Baptist Hospital of Miami
Michaelpa@baptisthealth.net

1

Disclosure statement
The following contributors have nothing to disclose regarding
any financial or nonfinancial relationships with the products
described, reviewed, or evaluated in this presentation:
 Michael Pasqualicchio, PharmD, BCPS
 Heidi Clarke, PharmD, BCCCP
 Jonathan Kline, PharmD, BCCCP
 Payal Patel, PharmD, BCCCP

2

Presentation objective

Evaluate the mortality associated with adding vasopressin
to both low-dose and high-dose vasopressors in patients
with septic shock
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Sepsis
 Uncontrolled, generalized, intravascular inflammatory
response to infection
 Most common cause of death in intensive care units (ICUs)1
 Increasing incidence over the last 10 years
 In-hospital mortality rate of greater than 40%2
 Most expensive condition to treat in 2013: $24 billion in annual costs3

 Treatment:
 Fluid resuscitation (30 ml/kg)
 Prompt administration of broad-spectrum antimicrobial agents
 Vasoactive medications
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Surviving Sepsis Guidelines
 Norepinephrine recommended as first-choice vasopressor
(strong recommendation, moderate quality of evidence)
 Suggest adding either vasopressin (weak recommendation, low
quality of evidence) or epinephrine (weak recommendation,
low quality of evidence)
 Raise MAP to target (recommended target of 65 mmHg)
 Decrease norepinephrine requirements
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Vasopressin mechanism
 Distinct mechanism compared to catecholamine agents
 Activates V1 receptors
 Induces constriction of vascular smooth muscle cells through
increased intra-cellular calcium and decreased nitric oxide induced
vasodilation

 Endogenous levels initially increase in response to hypotension
but quickly decline within 36 hours
 Maintains efficacy in acidotic state
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VASST trial
 Multi-center, randomized, double-blind trial
 Patients receiving norepinephrine at a minimum rate of 5 mcg/minute
were randomly divided into two groups:
 Low-dose vasopressin (in addition to open-label vasopressors)
 Norepinephrine (in addition to open-label vasopressors)

 Primary outcome: 28-day mortality after the initiation of study infusion
 Sub-group analysis that divided patients into additional two groups:
 Less severe shock: Norepinephrine rate 5-14 mcg/minute at randomization
 More severe shock : Norepinephrine rate ≥15 mcg/minute at randomization
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VASST trial results
Outcome

Norepinephrine
(n=382)

Vasopressin
(n=396)

p-value

Time to study drug infusion - hours

11.5 + 9.4

11.9 + 8.9

0.57

28-day mortality – no (%)

150 (39.3)

140 (35.4)

0.26

90-day mortality – no (%)

188 (49.6)

172 (43.9)

0.11

28-day mortality – no/total no (%)

85/200 (42.5)

88/200 (44.0)

0.76

90-day mortality – no/total no (%)

105/199 (52.8)

103/199 (51.8)

0.84

28-day mortality – no/total no (%)

65/182 (35.7)

52/196 (26.5)

0.05

90-day mortality – no/total no (%)

83/180 (46.1)

69/193 (35.8)

0.04

More severe shock – NE ≥ 15 mcg/minute

Less severe shock – NE 5-14 mcg/minute
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VANISH trial
 Factorial, double-blind, randomized trial
 Four groups:
 Vasopressin and hydrocortisone
 Vasopressin and placebo
 Norepinephrine and hydrocortisone
 Norepinephrine and placebo

 Primary outcome: Kidney failure-free days 28-days post
randomization
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VANISH trial results
Outcome

Vasopressin +
hydrocortisone
(n=100)

Vasopressin +
placebo
(n=104)

Norepinephrine +
hydrocortisone
(n=101)

Norepinephrine +
placebo
(n=103)

Time to study drug infusion
- hours

3.2 (1.8-5)

3.5 (2.5-5.4)

3.7 (1.7-5)

3.5 (1.4-5.4)

28-day mortality – no/total
no (%)

33/100 (33.0)

30/104 (28.8)

29/101 (28.7)

27/103 (26.2)

ICU mortality – no/total no
(%)

32/100 (32.0)

26/104 (25.0)

24/101 (23.8)

27/103 (26.2)

Hospital mortality –
no/total no (%)

35/100 (35.0)

33/104 (31.7)

31/101 (30.7)

29/103 (28.2)

50 (28-92)

59 (27-112)

46 (23-72)

44 (23-90)

Time to shock reversal hours
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Additional studies
Trial

Comparison

Outcomes

Reardon et al.9
Single-center, retrospective, chartreview
N=71

Vasopressin initiation within 
6 hours of shock onset vs.
vasopressin within 6-48

hours of shock onset


Early vasopressin resulted in significantly less new-onset
arrhythmias
No difference in duration of catecholamine and
vasopressin therapy
No difference in mortality or ICU/hospital length of stay

Hammond et al.10
Single-center, prospective, openlabel study
N=82

Early addition of vasopressin 
within 4 hours of septic
shock onset vs.

norepinephrine
monotherapy

Significantly shorter time to MAP target (7.6 vs. 5.7 hours;
p=0.058)
No difference in mortality, norepinephrine duration,
vasopressin duration, or ICU/hospital length of stay

Hammond et al.11
Single-center, retrospective, cohort
study
N=96

Early addition of vasopressin 
within 4 hours of septic
shock onset vs.

norepinephrine
monotherapy


Significantly shorter time to MAP target and hospital
length of stay but no difference in ICU length of stay
Significantly greater reduction in SOFA score at 72 hours
post shock onset
No difference in SOFA score at 6, 24, or 72 hours post
shock onset
No difference in in-hospital or 28-day mortality
No difference in norepinephrine duration
No difference in time to MAP target, mortality, or
ICU/hospital length of stay

Wu et al.12
Single-center, retrospective, cohort
study
N=148

Vasopressin initiation for
patients requiring ≥10
mcg/min of norepinephrine
vs. patients requiring ≥50
mcg/min of norepinephrine





Study rationale
Conflicting evidence and lack of recommendations regarding:
 Optimal candidates for vasopressin
 Optimal timing of vasopressin initiation
 Optimal timing of vasopressin discontinuation
High relative cost of vasopressin compared to other
vasopressors prioritizes its optimization
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Purpose
To evaluate outcomes for patients with septic shock based on
the utilization of vasopressin
Research questions:
 Does the addition of vasopressin to low-dose vasopressors in
patients with septic shock reduce in-hospital mortality?
 Does the addition of vasopressin to high-dose vasopressors in
patients with septic shock reduce in-hospital mortality?
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Design
Design: IRB-exempt, retrospective chart review of patients treated with
vasopressors and diagnosed with septic shock

Time frame: January 1, 2018 to September 17, 2018
Setting: Intensive care unit (ICU) at Baptist Hospital of Miami

Sample size: 149 patients
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Subject selection
Inclusion criteria
• ≥ 18 years old
• “Septic shock” documented in the medical record
• Vasopressor infusion

Exclusion criteria
•
•
•
•

Pregnant
“Cardiogenic shock” documented in the medical record
Post-cardiothoracic surgery
<12 hours on vasopressors
15

Comparator groups
Low-dose vasopressors:
≤ 0.2 mcg/kg/minute NE equivalents
• Patients treated with vasopressin
• Patients treated without vasopressin

High-dose vasopressors:

> 0.2 mcg/kg/minute NE equivalents
• Patients treated with vasopressin
• Patients treated without vasopressin
NE-norepinephrine

16

Study outcomes
Primary outcome:
 In-hospital mortality from any cause or initiation of hospice
care

Secondary outcomes:
 Total time on vasopressors (hours)
 Number of catecholamine agents required
 ICU length of stay (days)
 Hospital length of stay (days)
17

Subject selection
Excluded (n=849)







<18 years old
<12 hours on vasopressors
No septic shock diagnosis
Post-cardiothoracic surgery
Cardiogenic shock diagnosis
No vasopressors initiated

Low-dose vasopressor
arm
n=55

No vasopressin
n=35

Vasopressin
n=20

Initial review
n=998

Septic shock accounted for
~38% of vasopressin
utilization over this time
period

Included
n=149

High-dose vasopressor
arm
n=94

No vasopressin
n=46

Vasopressin
n=48

Results: Low-dose arm
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Baseline characteristics: Low-dose arm
Characteristics

No vasopressin
(n=35)

Vasopressin
(n=20)

p-value

70.7 + 13.7

63.7 + 18.7

0.12

Male sex – no (%)

23 (65.7)

11 (55)

0.43

APACHE II score

18.1 + 5.8

18.1 + 7.0

1.00

SOFA score

5.1 + 2.2

5.6 + 2.6

0.45

Lactic acid – mg/dL

3.0 + 1.9

3.2 + 2.6

0.74

MAP – mmHg

65.3 + 12.0

63.7 + 8.8

0.60

NE-equivalent dose – mcg/kg/min

10.4 + 5.4

10.6 + 7.8

0.91

Age - years

All baseline characteristics at time of vasopressor initiation
All values displayed as mean + standard deviation unless otherwise noted
NE-equivalent dose equation from VASST trial
NE-equivalent = Norepinephrine + Epinephrine + (Dopamine/2) + (Phenylephrine/10)
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Outcomes: Low-dose arm
No vasopressin
(n=35)

Vasopressin
(n=20)

p-value

7 (20.0)

7 (35.0)

0.22

No vasopressin
(n=35)

Vasopressin
(n=20)

p-value

Mean time on vasopressors - hours

52.6 + 56.3

75.5 + 40.2

0.12

Mean time on vasopressors for patients
surviving to discharge - hours

45.3 + 38.4

66.9 + 41.2

0.06

3.6 + 2.8

10.1 + 9.0

0.0002

12.8 + 12.5
One agent: 35 (100)

30.6 + 27.4
No other agents: 4 (20)
One agent: 14 (70)
Two agents: 2 (10)
One agent: 10 (50)
Two agents: 9 (45)
Three agents: 1 (5)

0.001

In-hospital mortality – no (%)

Secondary outcomes

Mean ICU length of stay - days
Mean hospital length of stay - days
Number of catecholamines at time of
inclusion
Maximum number of catecholamines
following inclusion

One agent: 34 (97)
Two agents: 1 (3)
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Additional data: Low-dose arm
Steroids administered – no (%)

No vasopressin
(n=35)

Vasopressin
(n=20)

17 (49)

9 (45)

9 (26)

2 (10)

Midodrine administered – no (%)
Average norepinephrine rate of 2.6 mcg/min at
initiation

Mean time to vasopressin administration - hours (range)
Mean duration of vasopressin – hours (range)

10.8 (0-45.3)
40.7 (12.3-90.8)
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Results: High-dose arm
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Baseline characteristics: High-dose arm
Characteristics

No vasopressin
(n=46)

Vasopressin
(n=48)

p-value

75.8 + 10.8

73.2 + 14.2

0.18

Male sex – no (%)

32 (69.6)

27 (56.3)

0.16

APACHE II score

21.2 + 6.0

22.6 + 6.5

0.28

SOFA score

6.0 + 2.3

6.5 + 3.1

0.38

Lactic acid – mg/dL

3.1 + 1.9

4.7 + 4.6

0.03

MAP – mmHg

67.1 + 15.5

66.8 + 15.3

0.93

NE-equivalent dose – mcg/kg/min

42.4 + 49.2

58.2 + 53.3

0.14

Age - years

All baseline characteristics at time of vasopressor initiation
All values displayed as mean + standard deviation unless otherwise noted
NE-equivalent dose equation from VASST trial
NE-equivalent = Norepinephrine + Epinephrine + (Dopamine/2) + (Phenylephrine/10)
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Outcomes: High-dose arm
No vasopressin
(n=46)

Vasopressin
(n=48)

p-value

20 (43.5)

34 (70.8)

0.007

No vasopressin
(n=46)

Vasopressin
(n=48)

p-value

Number of catecholamines at time of
inclusion

95.4 + 86.8
Median: 74.2
81.9 + 71.8
Median: 70.6
7.3 + 6.8
Median: 5.0
17.5 + 12.0
Median: 14.0
One agent: 35 (76)
Two agents: 11 (24)

171.7 + 211.2
Median: 76.5
141.6 + 142.1
Median: 70.5
9.4 + 15.2
Median: 5.0
16.1 + 16.6
Median: 12.0
One agent: 35 (73)
Two agents: 13 (27)

Maximum number of catecholamines
following inclusion

One agent: 37 (72)
Two agents: 13 (28)

One agent: 22 (46)
Two agents: 21 (44)
Three agents: 4 (8)
Four agents: 1 (2)

In-hospital mortality – no (%)

Secondary outcomes
Mean time on vasopressors - hours
Mean time on vasopressors for patients
surviving to discharge - hours
Mean ICU length of stay - days
Mean hospital length of stay - days

0.39
0.64

Additional data: High-dose arm
No vasopressin
(n=46)

Vasopressin
(n=48)

Steroids administered – no (%)

21 (45.7)

25 (52.1)

Midodrine administered – no (%)

20 (43.5)

19 (39.6)

Mean time to vasopressin administration - hours (range)
Mean duration of vasopressin – hours (range)

24.7 (0-177.3)
62.4 (1.8-403)
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Limitations
 Higher vasopressin dose utilized than recommended by the
Surviving Sepsis Guidelines
 Small sample size in low-dose vasopressor with vasopressin group
(n=20)
 Potential for inaccurate charting of vasopressor initiation, rate
change, and discontinuation
 Potential for inaccurate reporting of septic shock diagnosis in
electronic medical record
 Unknown administration of fluid resuscitation prior to initiation of
vasopressors
 Additional causes of mortality not accounted for
 Evaluated in-hospital mortality with unknown extended outcomes
27

Conclusions
 No in-hospital mortality benefit associated with vasopressin
utilization in both the low- and high-dose arms
 No difference in duration of vasopressor therapy associated
with vasopressin administration in both the low- and highdose arms
 Opportunity for optimization of vasopressin utilization based
on poor associated outcomes
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Self-assessment question
 Which of the following is an outcome of the VASST trial?
A. 28-day mortality benefit seen with initiation of vasopressin prior to
norepinephrine
B. Increased 28-day mortality for patients administered vasopressin
C. Significantly more days free of organ dysfunction for patients
administered vasopressin
D. 90-day mortality benefit for patients with less-severe septic shock
administered vasopressin
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Self-assessment answer
 Which of the following is an outcome of the VASST trial?
A. 28-day mortality benefit seen with initiation of vasopressin prior to
norepinephrine
B. Increased 28-day mortality for patients administered vasopressin
C. Significantly more days free of organ dysfunction for patients
administered vasopressin
D. 90-day mortality benefit for patients with less-severe septic shock
administered vasopressin
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